In these proceedings of the 6th Congress of the European Committee for Treatment and Research in Multiple Sclerosis three main aspects of the disease are presented and discussed. Early diagnosis: Growing experience in early diagnostic methods raises several problems. When and to what extent should investigations be performed? And should the diagnostic results be revealed to the patient in full detail? Symptomatic treatment: Despite the scarcity of new developments many hospitals neglect the principles of symptomatic treatment or consider them as less important. A review of the basic symptomatic therapy is given. New developments: Therapies under examination (Corticosteroids, Azathioprine and Cyclophosphamide) or experimental therapies (Mitoxantrone) are described and discussed. Vaccination with T-cell receptor epitopes are presented in animals and human experimental settings. The congress contributions reflect research activities in all the major fields of MS. The book is also of considerable interest for neurologists and physicians actively involved in the treatment of MS patients.
Welcome address. DIAGNOSIS. Ethics. (2 papers, 2 contributors) Methods. a. MRI (5 papers, 21 con.) b. Spectrometry (2 papers, 11 con.) c. PET (1 paper, 12 con.) d. Neurophysiology (7 papers, 30 con.) e. CSF and serum (13 papers, 53 con.) f. HLA (2 papers, 11 con.) Optic neuritis (2 papers, 12 con.) Neuropsychology (5 papers, 15 con.) SYMPTOMATIC TREATMENT. Ataxia and tremor (2 papers, 2 con.) Spasticity and pain (3 papers, 5 con.) Urinary tract (2 papers, 7 con.) NEW DEVELOPMETS. Therapies under examination. a. Steroids (6 papers, 23 con.) b. Azathioprine/Cyclosporine (2 papers, 9 con.) Experimental therapies. a. Mitoxanthrone (3 papers, 14 con.) b. Sulfosalazine (1 paper, 4 con.) c. Mab (1 paper, 7 con.) d. Irradiation (1 paper, 10 con.) Basic Research (7 papers, 42 con.) Experimental animal research (10 papers, 42 con.) MISCELLANEOUS. (3 papers, 9 con.) Index of authors.
「Nielsen BookData」 より